HighPoint Advisor Group LLC Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

HighPoint Advisor Group LLC increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 795 shares of the company’s stock after purchasing an additional 158 shares during the period. HighPoint Advisor Group LLC’s holdings in Medpace were worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Proficio Capital Partners LLC raised its stake in shares of Medpace by 34,497.4% during the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after buying an additional 241,827 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Medpace during the fourth quarter valued at approximately $78,144,000. Norges Bank acquired a new position in Medpace in the fourth quarter valued at approximately $69,859,000. GW&K Investment Management LLC boosted its position in Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after purchasing an additional 133,379 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Price Performance

NASDAQ MEDP opened at $304.11 on Friday. Medpace Holdings, Inc. has a 1-year low of $289.01 and a 1-year high of $459.77. The company has a market cap of $9.27 billion, a PE ratio of 24.08, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45. The stock’s 50 day simple moving average is $332.70 and its 200-day simple moving average is $338.09.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on MEDP shares. Leerink Partnrs raised shares of Medpace to a “hold” rating in a report on Monday, March 24th. Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Finally, Leerink Partners assumed coverage on Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price target for the company. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.